Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingAspirus Arise Aldurazyme Coverage Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentAspirus ArisePolicy N/A

    Aldurazyme (laronidase) — Enzyme Replacement Therapy for MPS I

    Customize your policy alerts

    Sign up for all Aspirus Arise policy alerts

    Know when Aspirus Arise releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity criteria for coverage of Aldurazyme (laronidase) for treatment of Mucopolysaccharidosis type I (MPS I) for Aspirus Medicare plans and applies to providers prescribing or requesting authorization.

    Policy Summary
    PayerAspirus Arise
    PolicyAldurazyme (laronidase) — Enzyme Replacement Therapy for MPS I
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateJan 1, 2021
    Last ReviewSep 15, 2025
    Next Review DateSep 15, 2025
    Key ActionObtain prior authorization and document diagnostic confirmation (enzyme assay or biallelic IDUA variants) and specialist prescriber or consultation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yrinitial approval duration
    0.58 mg/kgmax dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    weekly
    frequency
    Aspirus Medicareplans covered

    Coverage Criteria for Aldurazyme (laronidase)

    Initial Approval Criteria (FDA-Approved Indication)

    Covered when ALL of the following are met

    FDA-Approved Indication: Patient has Mucopolysaccharidosis Type I (Hurler, Hurler-Scheie, or Scheie). Approve for 1 year if both A and B are met.
    A. Diagnostic confirmation: Diagnosis is established by ONE of: (i) laboratory test demonstrating deficient α-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum; OR (ii) molecular genetic test demonstrating biallelic pathogenic or likely pathogenic IDUA gene variants.
    B. Prescriber requirement: Aldurazyme is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.
    Dosing limits: Each dose must not exceed 0.58 mg/kg administered intravenously no more frequently than once weekly.0.58 mg/kg; <= once weekly

    Approval duration: 1 year if criteria met.

    Coverage is not recommended for circumstances that are not listed in the Recommended Authorization Criteria. Requests for Aldurazyme outside the criteria described in this policy may be denied; the criteria will be updated as new published data become available.

    Confirmation of MPS I diagnosis via molecular genetic testing of IDUA

    Diagnostic requirement (molecular): Molecular genetic testing must demonstrate biallelic pathogenic or likely pathogenic variants in the IDUA gene to establish diagnosis by genetic testing.

    This molecular finding is accepted as an equivalent diagnostic criterion to deficient enzyme activity.

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior authorization recommended; approve 1 year if criteria and dosing met

    Prior authorization is recommended for medical benefit coverage of Aldurazyme; approve for 1 year when the patient meets the policy criteria and dosing limits. Approvals may be extended if the patient continues to meet criteria; requests for doses outside the documented dosing will be considered case-by-case by a clinician.

    • Approval duration: 1 year when criteria met; extended approvals allowed if criteria continue to be met.
    • Dose requests outside established dosing (see dosing limit block) require case-by-case clinical review.
    Step Therapy

    Relation to HSCT: HSCT indicated for severe early disease; Aldurazyme appropriate in specific pre/post-HSCT scenarios

    HSCT is an indicated therapy for severe forms of MPS I in children <2 years who are cognitively intact. Aldurazyme is appropriate in certain pre- or post-HSCT contexts — e.g., for children <2 years who are cognitively intact with severe physical disease prior to HSCT or for children who have already experienced cognitive decline — and is recommended in older patients regardless of cognitive status.

    Background

    Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disease caused by deficiency of α-L-iduronidase, resulting in accumulation of glycosaminoglycans and progressive multiorgan dysfunction. The clinical spectrum ranges from severe (Hurler) to attenuated (Hurler–Scheie and Scheie) phenotypes. Diagnosis is established either by demonstrating deficient α-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum, or by molecular genetic testing showing biallelic pathogenic or likely pathogenic IDUA variants. Treatment options include hematopoietic stem cell transplantation (HSCT) for selected early severe cases and enzyme replacement therapy with Aldurazyme (laronidase) for somatic manifestations; when covered under this policy, Aldurazyme is approved for up to 1 year when criteria are met, with dosing limited to 0.58 mg/kg per dose administered intravenously no more frequently than once weekly.

    Definitions and Diagnostic Criteria

    Definitive diagnosis of MPS I — Diagnostic criteria
    Definitive diagnostic methodsDemonstration of deficient α-L-iduronidase activity in fibroblasts, leukocytes, plasma, or serum; OR molecular genetic testing demonstrating biallelic pathogenic or likely pathogenic IDUA gene variants.
    Enzyme assay specimen typesDiagnostic enzyme activity testing may be performed on leukocytes, fibroblasts, plasma, or serum.
    Genetic testing requirementMolecular genetic testing must demonstrate biallelic pathogenic or likely pathogenic variants in the IDUA gene to confirm diagnosis.
    Context of diagnosisDiagnosis of MPS I (Hurler, Hurler-Scheie, or Scheie) is based on either enzyme deficiency or biallelic IDUA variants.

    Covered Indications

    Confirmation of MPS I diagnosis via molecular genetic testing of IDUA

    For coverage consideration, molecular testing must meet the following diagnostic standard:

    Accepted molecular diagnostic criterion: Demonstration of biallelic pathogenic or likely pathogenic IDUA gene variants (i.e., pathogenic or likely pathogenic variants on both alleles) is required to confirm MPS I by molecular genetic testing.

    When molecular testing is used to establish diagnosis, results must document pathogenicity classification for both alleles.

    Eligibility Requirements

    This block is reserved for an eligibility summary. There are no top-level eligibility nodes beyond the detailed coverage criteria in this policy; eligibility for Aldurazyme coverage requires meeting the diagnostic confirmation, prescriber, and dosing limits specified in the Recommended Authorization Criteria.

    Policy Summary
    PayerAspirus Arise
    PolicyAldurazyme (laronidase) — Enzyme Replacement Therapy for MPS I
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateJan 1, 2021
    Last ReviewSep 15, 2025
    Next Review DateSep 15, 2025
    Key ActionObtain prior authorization and document diagnostic confirmation (enzyme assay or biallelic IDUA variants) and specialist prescriber or consultation.
    SourceLink
    On This Page
    Coverage Criteria for Aldurazyme (laronidase)Provider Actions and Authorization RequirementsBackgroundDefinitions and Diagnostic CriteriaCovered IndicationsEligibility Requirements
    • HSCT preserves intellectual development and is indicated for severe MPS I in children <2 years who are cognitively intact.
    • Aldurazyme does not cross the blood–brain barrier and may be used pre- or post-HSCT in specified clinical scenarios.
    Documentation Required

    Required diagnostic documentation and specialist prescriber

    Documentation must demonstrate the diagnosis by either deficient α-L-iduronidase enzyme activity in leukocytes, fibroblasts, plasma, or serum OR by molecular genetic testing showing biallelic pathogenic or likely pathogenic IDUA variants; additionally, include that Aldurazyme is prescribed by or in consultation with an appropriate specialist.

    • Acceptable diagnostic evidence: (a) enzyme assay showing deficient α-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum; OR (b) molecular genetic testing demonstrating biallelic pathogenic/likely pathogenic IDUA variants.
    • Prescriber requirement: must be prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or physician who treats lysosomal storage disorders.
    Denial Risk

    Non-listed indications may be denied

    Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria; requests outside the listed criteria may be denied and criteria will be updated as new data become available.

    • Requests for indications or clinical scenarios not specified in the policy’s Recommended Authorization Criteria are not recommended for approval.
    Note

    Specialist prescriber required

    Aldurazyme must be prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or other physician who specializes in the treatment of lysosomal storage disorders.

    • Because of the specialized skills required for evaluation, diagnosis, and monitoring, approval requires prescription by or consultation with an appropriate specialist.